

SECOND REGULAR SESSION

SENATE BILL NO. 887

95TH GENERAL ASSEMBLY

INTRODUCED BY SENATOR SCHAEFER.

Read 1st time February 3, 2010, and ordered printed.

TERRY L. SPIELER, Secretary.

3342S.02I

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to the designation of controlled substances, with penalty provisions.

Be it enacted by the General Assembly of the State of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section
2 enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a
2 substance in Schedule I if it finds that the substance:

3 (1) Has high potential for abuse; and

4 (2) Has no accepted medical use in treatment in the United States or
5 lacks accepted safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in
8 Schedule I;

9 (2) Any of the following opiates, including their isomers, esters, ethers,
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,
11 whenever the existence of these isomers, esters, ethers and salts is possible
12 within the specific chemical designation:

13 (a) Acetyl-alpha-methylfentanyl;

14 (b) Acetylmethadol;

15 (c) Allylprodine;

16 (d) Alphacetylmethadol;

17 (e) Alphameprodine;

18 (f) Alphamethadol;

19 (g) Alpha-methylfentanyl;

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.

- 20 (h) Alpha-methylthiofentanyl;
21 (i) Benzethidine;
22 (j) Betacetylmethadol;
23 (k) Beta-hydroxyfentanyl;
24 (l) Beta-hydroxy-3-methylfentanyl;
25 (m) Betameprodine;
26 (n) Betamethadol;
27 (o) Betaprodine;
28 (p) Clonitazene;
29 (q) Dextromoramide;
30 (r) Diampromide;
31 (s) Diethylthiambutene;
32 (t) Difenoxin;
33 (u) Dimenoxadol;
34 (v) Dimepheptanol;
35 (w) Dimethylthiambutene;
36 (x) Dioxaphetyl butyrate;
37 (y) Dipipanone;
38 (z) Ethylmethylthiambutene;
39 (aa) Etonitazene;
40 (bb) Etoxidine;
41 (cc) Furethidine;
42 (dd) Hydroxypethidine;
43 (ee) Ketobemidone;
44 (ff) Levomoramide;
45 (gg) Levophenacetylmorphan;
46 (hh) 3-Methylfentanyl;
47 (ii) 3-Methylthiofentanyl;
48 (jj) Morpheridine;
49 (kk) MPPP;
50 (ll) Noracetylmethadol;
51 (mm) Norlevorphanol;
52 (nn) Normethadone;
53 (oo) Norpipanone;
54 (pp) Para-fluorofentanyl;
55 (qq) PEPAP;

- 56 (rr) Phenadoxone;
- 57 (ss) Phenampromide;
- 58 (tt) Phenomorphan;
- 59 (uu) Phenoperidine;
- 60 (vv) Piritramide;
- 61 (ww) Proheptazine;
- 62 (xx) Properidine;
- 63 (yy) Propiram;
- 64 (zz) Racemoramide;
- 65 (aaa) Thiofentanyl;
- 66 (bbb) Tilidine;
- 67 (ccc) Trimeperidine;
- 68 (3) Any of the following opium derivatives, their salts, isomers and salts
69 of isomers unless specifically excepted, whenever the existence of these salts,
70 isomers and salts of isomers is possible within the specific chemical designation:
- 71 (a) Acetorphine;
- 72 (b) Acetyldihydrocodeine;
- 73 (c) Benzylmorphine;
- 74 (d) Codeine methylbromide;
- 75 (e) Codeine-N-Oxide;
- 76 (f) Cyprenorphine;
- 77 (g) Desomorphine;
- 78 (h) Dihydromorphine;
- 79 (i) Drotebanol;
- 80 (j) Etorphine (except hydrochloride salt);
- 81 (k) Heroin;
- 82 (l) Hydromorphenol;
- 83 (m) Methyldesorphine;
- 84 (n) Methyldihydromorphine;
- 85 (o) Morphine methylbromide;
- 86 (p) Morphine methylsulfonate;
- 87 (q) Morphine-N-Oxide;
- 88 (r) Myrophine;
- 89 (s) Nicocodeine;
- 90 (t) Nicomorphine;
- 91 (u) Normorphine;

- 92 (v) Pholcodine;
- 93 (w) Thebacon;
- 94 (4) Any material, compound, mixture or preparation which contains any
95 quantity of the following hallucinogenic substances, their salts, isomers and salts
96 of isomers, unless specifically excepted, whenever the existence of these salts,
97 isomers, and salts of isomers is possible within the specific chemical designation:
- 98 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 99 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 100 (c) 2,5-dimethoxyamphetamine;
- 101 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 102 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 103 (f) 4-methoxyamphetamine;
- 104 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 105 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 106 (i) 3,4-methylenedioxyamphetamine;
- 107 (j) 3,4-methylenedioxymethamphetamine;
- 108 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 109 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 110 (m) 3,4,5-trimethoxyamphetamine;
- 111 (n) **5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its**
112 **isomers, salts, and salts of isomers;**
- 113 (o) Alpha-ethyltryptamine;
- 114 [(o)] (p) Alpha-methyltryptamine;
- 115 [(p)] (q) Bufotenine;
- 116 [(q)] (r) Diethyltryptamine;
- 117 [(r)] (s) Dimethyltryptamine;
- 118 [(s)] (t) 5-methoxy-N,N-diisopropyltryptamine;
- 119 [(t)] (u) Ibogaine;
- 120 (v) **1-butyl-3(1-naphthoyl)indole;**
- 121 (w) **1-pentyl-3(1-naphthoyl)indole;**
- 122 [(u)] (x) Lysergic acid diethylamide;
- 123 [(v)] (y) Marijuana or marihuana;
- 124 [(w)] (z) Mescaline;
- 125 [(x)] (aa) Parahexyl;
- 126 [(y)] (bb) Peyote, to include all parts of the plant presently classified
127 botanically as Lophophora Williamsii Lemaire, whether growing or not; the seeds

128 thereof; any extract from any part of such plant; and every compound,
129 manufacture, salt, derivative, mixture or preparation of the plant, its seed or
130 extracts;

131 **(cc) Phenol, CP 47, 497 & homologues, or 2-[(1R,3S)-3-**
132 **hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5,**
133 **and homologues where side chain n-4,6, or 7;**

134 [(z)] **(dd)** N-ethyl-3-piperidyl benzilate;

135 [(aa)] **(ee)** N-methyl-3-piperidyl benzilate;

136 [(bb)] **(ff)** Psilocybin;

137 [(cc)] **(gg)** Psilocyn;

138 [(dd)] **(hh)** Tetrahydrocannabinols naturally contained in a plant of the
139 genus Cannabis (cannabis plant), as well as synthetic equivalents of the
140 substances contained in the cannabis plant, or in the resinous extractives of such
141 plant, or synthetic substances, derivatives, and their isomers with similar
142 chemical structure and pharmacological activity to those substances contained in
143 the plant, such as the following:

144 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;

145 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;

146 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;

147 d. Any compounds of these structures, regardless of numerical designation
148 of atomic positions covered;

149 [(ee)] **(ii)** Ethylamine analog of phencyclidine;

150 [(ff)] **(jj)** Pyrrolidine analog of phencyclidine;

151 [(gg)] **(kk)** Thiophene analog of phencyclidine;

152 [(hh)] **(ll)** 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

153 [(ii)] **(mm)** Salvia divinorum;

154 [(jj)] **(nn)** Salvinorin A;

155 (5) Any material, compound, mixture or preparation containing any
156 quantity of the following substances having a depressant effect on the central
157 nervous system, including their salts, isomers and salts of isomers whenever the
158 existence of these salts, isomers and salts of isomers is possible within the
159 specific chemical designation:

160 (a) Gamma-hydroxybutyric acid;

161 (b) Mecloqualone;

162 (c) Methaqualone;

163 (6) Any material, compound, mixture or preparation containing any

164 quantity of the following substances having a stimulant effect on the central
165 nervous system, including their salts, isomers and salts of isomers:

- 166 (a) Aminorex;
167 (b) N-benzylpiperazine;
168 (c) Cathinone;
169 (d) Fenethylamine;
170 (e) Methcathinone;
171 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
172 oxazolamine);
173 (g) N-ethylamphetamine;
174 (h) N,N-dimethylamphetamine;

175 (7) A temporary listing of substances subject to emergency scheduling
176 under federal law shall include any material, compound, mixture or preparation
177 which contains any quantity of the following substances:

- 178 (a) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its
179 optical isomers, salts and salts of isomers;
180 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
181 (thenylfentanyl), its optical isomers, salts and salts of isomers;
182 (8) Khat, to include all parts of the plant presently classified botanically
183 as *catha edulis*, whether growing or not; the seeds thereof; any extract from any
184 part of such plant; and every compound, manufacture, salt, derivative, mixture,
185 or preparation of the plant, its seed or extracts.

186 3. The department of health and senior services shall place a substance
187 in Schedule II if it finds that:

- 188 (1) The substance has high potential for abuse;
189 (2) The substance has currently accepted medical use in treatment in the
190 United States, or currently accepted medical use with severe restrictions; and
191 (3) The abuse of the substance may lead to severe psychic or physical
192 dependence.

193 4. The controlled substances listed in this subsection are included in
194 Schedule II:

195 (1) Any of the following substances whether produced directly or indirectly
196 by extraction from substances of vegetable origin, or independently by means of
197 chemical synthesis, or by combination of extraction and chemical synthesis:

- 198 (a) Opium and opiate and any salt, compound, derivative or preparation
199 of opium or opiate, excluding apomorphine, thebaine-derived butorphanol,

200 dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and their
201 respective salts but including the following:

- 202 a. Raw opium;
- 203 b. Opium extracts;
- 204 c. Opium fluid;
- 205 d. Powdered opium;
- 206 e. Granulated opium;
- 207 f. Tincture of opium;
- 208 g. Codeine;
- 209 h. Ethylmorphine;
- 210 i. Etorphine hydrochloride;
- 211 j. Hydrocodone;
- 212 k. Hydromorphone;
- 213 l. Metopon;
- 214 m. Morphine;
- 215 n. Oxycodone;
- 216 o. Oxymorphone;
- 217 p. Thebaine;

218 (b) Any salt, compound, derivative, or preparation thereof which is
219 chemically equivalent or identical with any of the substances referred to in this
220 subdivision, but not including the isoquinoline alkaloids of opium;

221 (c) Opium poppy and poppy straw;

222 (d) Coca leaves and any salt, compound, derivative, or preparation of coca
223 leaves, and any salt, compound, derivative, or preparation thereof which is
224 chemically equivalent or identical with any of these substances, but not including
225 decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

226 (e) Concentrate of poppy straw (the crude extract of poppy straw in either
227 liquid, solid or powder form which contains the phenanthrene alkaloids of the
228 opium poppy);

229 (2) Any of the following opiates, including their isomers, esters, ethers,
230 salts, and salts of isomers, whenever the existence of these isomers, esters, ethers
231 and salts is possible within the specific chemical designation, dextrorphan and
232 levopropoxyphene excepted:

- 233 (a) Alfentanil;
- 234 (b) Alphaprodine;
- 235 (c) Anileridine;

- 236 (d) Bezitramide;
- 237 (e) Bulk dextropropoxyphene;
- 238 (f) Carfentanil;
- 239 (g) Butyl nitrite;
- 240 (h) Dihydrocodeine;
- 241 (i) Diphenoxylate;
- 242 (j) Fentanyl;
- 243 (k) Isomethadone;
- 244 (l) Levo-alphacetylmethadol;
- 245 (m) Levomethorphan;
- 246 (n) Levorphanol;
- 247 (o) Metazocine;
- 248 (p) Methadone;
- 249 (q) Meperidine;
- 250 (r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-
- 251 diphenylbutane;
- 252 (s) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--
- 253 carboxylic acid;
- 254 (t) Pethidine (meperidine);
- 255 (u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 256 (v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 257 (w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic
- 258 acid;
- 259 (x) Phenazocine;
- 260 (y) Piminodine;
- 261 (z) Racemethorphan;
- 262 (aa) Racemorphan;
- 263 (bb) Remifentanil;
- 264 (cc) Sufentanil;
- 265 **(dd) Tapentadol;**
- 266 (3) Any material, compound, mixture, or preparation which contains any
- 267 quantity of the following substances having a stimulant effect on the central
- 268 nervous system:
- 269 (a) Amphetamine, its salts, optical isomers, and salts of its optical
- 270 isomers;
- 271 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;

- 272 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
273 (d) Phenmetrazine and its salts;
274 (e) Methylphenidate;
- 275 (4) Any material, compound, mixture, or preparation which contains any
276 quantity of the following substances having a depressant effect on the central
277 nervous system, including its salts, isomers, and salts of isomers whenever the
278 existence of those salts, isomers, and salts of isomers is possible within the
279 specific chemical designation:
- 280 (a) Amobarbital;
281 (b) Glutethimide;
282 (c) Pentobarbital;
283 (d) Phencyclidine;
284 (e) Secobarbital;
- 285 (5) Any material or compound which contains any quantity of nabilone;
- 286 (6) Any material, compound, mixture, or preparation which contains any
287 quantity of the following substances:
- 288 (a) Immediate precursor to amphetamine and methamphetamine:
289 Phenylacetone;
- 290 (b) Immediate precursors to phencyclidine (PCP):
291 a. 1-phenylcyclohexylamine;
292 b. 1-piperidinocyclohexanecarbonitrile (PCC).
- 293 5. The department of health and senior services shall place a substance
294 in Schedule III if it finds that:
- 295 (1) The substance has a potential for abuse less than the substances listed
296 in Schedules I and II;
- 297 (2) The substance has currently accepted medical use in treatment in the
298 United States; and
- 299 (3) Abuse of the substance may lead to moderate or low physical
300 dependence or high psychological dependence.
- 301 6. The controlled substances listed in this subsection are included in
302 Schedule III:
- 303 (1) Any material, compound, mixture, or preparation which contains any
304 quantity of the following substances having a potential for abuse associated with
305 a stimulant effect on the central nervous system:
- 306 (a) Benzphetamine;
307 (b) Chlorphentermine;

- 308 (c) Clortermine;
- 309 (d) Phendimetrazine;
- 310 (2) Any material, compound, mixture or preparation which contains any
- 311 quantity or salt of the following substances or salts having a depressant effect on
- 312 the central nervous system:
- 313 (a) Any material, compound, mixture or preparation which contains any
- 314 quantity or salt of the following substances combined with one or more active
- 315 medicinal ingredients:
- 316 a. Amobarbital;
- 317 b. Secobarbital;
- 318 c. Pentobarbital;
- 319 (b) Any suppository dosage form containing any quantity or salt of the
- 320 following:
- 321 a. Amobarbital;
- 322 b. Secobarbital;
- 323 c. Pentobarbital;
- 324 (c) Any substance which contains any quantity of a derivative of
- 325 barbituric acid or its salt;
- 326 (d) Chlorhexadol;
- 327 (e) Embutramide;
- 328 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers
- 329 contained in a drug product for which an application has been approved under
- 330 Section 505 of the federal Food, Drug, and Cosmetic Act;
- 331 (g) Ketamine, its salts, isomers, and salts of isomers;
- 332 (h) Lysergic acid;
- 333 (i) Lysergic acid amide;
- 334 (j) Methyprylon;
- 335 (k) Sulfondiethylmethane;
- 336 (l) Sulfonethylmethane;
- 337 (m) Sulfonmethane;
- 338 (n) Tiletamine and zolazepam or any salt thereof;
- 339 (3) Nalorphine;
- 340 (4) Any material, compound, mixture, or preparation containing limited
- 341 quantities of any of the following narcotic drugs or their salts:
- 342 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not
- 343 more than ninety milligrams per dosage unit, with an equal or greater quantity

344 of an isoquinoline alkaloid of opium;

345 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not
346 more than ninety milligrams per dosage unit with one or more active, nonnarcotic
347 ingredients in recognized therapeutic amounts;

348 (c) Not more than three hundred milligrams of hydrocodone per one
349 hundred milliliters or not more than fifteen milligrams per dosage unit, with a
350 fourfold or greater quantity of an isoquinoline alkaloid of opium;

351 (d) Not more than three hundred milligrams of hydrocodone per one
352 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
353 or more active nonnarcotic ingredients in recognized therapeutic amounts;

354 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters
355 or not more than ninety milligrams per dosage unit, with one or more active
356 nonnarcotic ingredients in recognized therapeutic amounts;

357 (f) Not more than three hundred milligrams of ethylmorphine per one
358 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
359 or more active, nonnarcotic ingredients in recognized therapeutic amounts;

360 (g) Not more than five hundred milligrams of opium per one hundred
361 milliliters or per one hundred grams or not more than twenty-five milligrams per
362 dosage unit, with one or more active nonnarcotic ingredients in recognized
363 therapeutic amounts;

364 (h) Not more than fifty milligrams of morphine per one hundred milliliters
365 or per one hundred grams, with one or more active, nonnarcotic ingredients in
366 recognized therapeutic amounts;

367 (5) Any material, compound, mixture, or preparation containing any of the
368 following narcotic drugs or their salts, as set forth in subdivision (6) of this
369 subsection; buprenorphine;

370 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
371 pharmacologically related to testosterone (other than estrogens, progestins,
372 corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except
373 an anabolic steroid which is expressly intended for administration through
374 implants to cattle or other nonhuman species and which has been approved by
375 the Secretary of Health and Human Services for that administration. If any
376 person prescribes, dispenses, or distributes such steroid for human use, such
377 person shall be considered to have prescribed, dispensed, or distributed an
378 anabolic steroid within the meaning of this paragraph. Unless specifically
379 excepted or unless listed in another schedule, any material, compound, mixture

380 or preparation containing any quantity of the following substances, including its
381 salts, esters and ethers:

- 382 (a) $3\beta,17$ -dihydroxy- 5α -androstane;
383 (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
384 (c) 5α -androstan- $3,17$ -dione;
385 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
386 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
387 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
388 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
389 (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
390 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);
391 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);
392 (k) Bolasterone ($7\alpha, 17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
393 (l) Boldenone (17β -hydroxyandrost-1,4,-diene-3-one);
394 (m) Calusterone ($7\beta, 17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
395 (n) Clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
396 (o) Dehydrochloromethyltestosterone (4-chloro- 17β -hydroxy- 17α -methyl-
397 androst-1,4-dien-3-one);
398 (p) $\Delta 1$ -dihydrotestosterone (a.k.a. '1-testosterone')(17β -hydroxy- 5α -
399 androst-1-en-3-one);
400 (q) 4-dihydrotestosterone (17β -hydroxy-androstan-3-one);
401 (r) Drostanolone (17β -hydroxy- 2α -methyl- 5α -androstan-3-one);
402 (s) Ethylestrenol (17α -ethyl- 17β -hydroxyestr-4-ene);
403 (t) Fluoxymesterone (9-fluoro- 17α -methyl- $11\beta,17\beta$ -dihydroxyandrost-4-en-
404 3-one);
405 (u) Formebolone (2-formyl- 17α -methyl- $11\alpha,17\beta$ -dihydroxyandrost-1,4-dien-
406 3-one);
407 (v) Furazabol (17α -methyl- 17β -hydroxyandrostan- $[2,3-c]$ -furazan);
408 (w) 13β -ethyl- 17β -hydroxygon-4-en-3-one;
409 (x) 4-hydroxytestosterone (4, 17β -dihydroxy-androst-4-en-3-one);
410 (y) 4-hydroxy-19-nortestosterone (4, 17β -dihydroxy-estr-4-en-3-one);
411 (z) Mestanolone (17α -methyl- 17β -hydroxy-5-androstan-3-one);
412 (aa) Mesterolone (1α methyl- 17β -hydroxy- $[5\alpha]$ -androstan-3-one);
413 (bb) Methandienone (17α -methyl- 17β -hydroxyandrost-1,4-dien-3-one);
414 (cc) Methandriol (17α -methyl- $3\beta,17\beta$ -dihydroxyandrost-5-ene);
415 (dd) Methenolone (1-methyl- 17β -hydroxy- 5α -androst-1-en-3-one);

- 416 (ee) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
417 (ff) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
418 (gg) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
419 (hh) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -
420 hydroxyestr-4-en-3-one);
421 (ii) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
422 (jj) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
423 (kk) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
424 (ll) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
425 (mm) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -
426 androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
427 (nn) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
428 (oo) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
429 (pp) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
430 (qq) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
431 (rr) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
432 (ss) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
433 (tt) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
434 (uu) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
435 (vv) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
436 (ww) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
437 (xx) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
438 (yy) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
439 (zz) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
440 (aaa) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-
441 androstan-3-one);
442 (bbb) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-
443 pyrazole);
444 (ccc) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
445 (ddd) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
446 acid lactone);
447 (eee) Testosterone (17 β -hydroxyandrost-4-en-3-one);
448 (fff) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-
449 one);
450 (ggg) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
451 (hhh) Any salt, ester, or ether of a drug or substance described or listed

452 in this subdivision, except an anabolic steroid which is expressly intended for
453 administration through implants to cattle or other nonhuman species and which
454 has been approved by the Secretary of Health and Human Services for that
455 administration;

456 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
457 capsule in a United States Food and Drug Administration approved drug product;

458 (8) The department of health and senior services may except by rule any
459 compound, mixture, or preparation containing any stimulant or depressant
460 substance listed in subdivisions (1) and (2) of this subsection from the application
461 of all or any part of sections 195.010 to 195.320 if the compound, mixture, or
462 preparation contains one or more active medicinal ingredients not having a
463 stimulant or depressant effect on the central nervous system, and if the
464 admixtures are included therein in combinations, quantity, proportion, or
465 concentration that vitiate the potential for abuse of the substances which have
466 a stimulant or depressant effect on the central nervous system.

467 7. The department of health and senior services shall place a substance
468 in Schedule IV if it finds that:

469 (1) The substance has a low potential for abuse relative to substances in
470 Schedule III;

471 (2) The substance has currently accepted medical use in treatment in the
472 United States; and

473 (3) Abuse of the substance may lead to limited physical dependence or
474 psychological dependence relative to the substances in Schedule III.

475 8. The controlled substances listed in this subsection are included in
476 Schedule IV:

477 (1) Any material, compound, mixture, or preparation containing any of the
478 following narcotic drugs or their salts calculated as the free anhydrous base or
479 alkaloid, in limited quantities as set forth below:

480 (a) Not more than one milligram of difenoxin and not less than twenty-five
481 micrograms of atropine sulfate per dosage unit;

482 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-
483 methyl-2- propionoxybutane);

484 (c) Any of the following limited quantities of narcotic drugs or their salts,
485 which shall include one or more nonnarcotic active medicinal ingredients in
486 sufficient proportion to confer upon the compound, mixture or preparation
487 valuable medicinal qualities other than those possessed by the narcotic drug

488 alone:

489 a. Not more than two hundred milligrams of codeine per one hundred
490 milliliters or per one hundred grams;

491 b. Not more than one hundred milligrams of dihydrocodeine per one
492 hundred milliliters or per one hundred grams;

493 c. Not more than one hundred milligrams of ethylmorphine per one
494 hundred milliliters or per one hundred grams;

495 (2) Any material, compound, mixture or preparation containing any
496 quantity of the following substances, including their salts, isomers, and salts of
497 isomers whenever the existence of those salts, isomers, and salts of isomers is
498 possible within the specific chemical designation:

499 (a) Alprazolam;

500 (b) Barbitol;

501 (c) Bromazepam;

502 (d) Camazepam;

503 (e) **Carisoprodol**;

504 (f) Chloral betaine;

505 [(f)] (g) Chloral hydrate;

506 [(g)] (h) Chlordiazepoxide;

507 [(h)] (i) Clobazam;

508 [(i)] (j) Clonazepam;

509 [(j)] (k) Clorazepate;

510 [(k)] (l) Clotiazepam;

511 [(l)] (m) Cloxazolam;

512 [(m)] (n) Delorazepam;

513 [(n)] (o) Diazepam;

514 [(o)] (p) Dichloralphenazone;

515 [(p)] (q) Estazolam;

516 [(q)] (r) Ethchlorvynol;

517 [(r)] (s) Ethinamate;

518 [(s)] (t) Ethyl loflazepate;

519 [(t)] (u) Fludiazepam;

520 [(u)] (v) Flunitrazepam;

521 [(v)] (w) Flurazepam;

522 (x) **Fospropofol**;

523 [(w)] (y) Halazepam;

524 [(x)] (z) Haloxazolam;
525 [(y)] (aa) Ketazolam;
526 [(z)] (bb) Loprazolam;
527 [(aa)] (cc) Lorazepam;
528 [(bb)] (dd) Lormetazepam;
529 [(cc)] (ee) Mebutamate;
530 [(dd)] (ff) Medazepam;
531 [(ee)] (gg) Meprobamate;
532 [(ff)] (hh) Methohexital;
533 [(gg)] (ii) Methylphenobarbital (mephobarbital);
534 [(hh)] (jj) Midazolam;
535 [(ii)] (kk) Nimetazepam;
536 [(jj)] (ll) Nitrazepam;
537 [(kk)] (mm) Nordiazepam;
538 [(ll)] (nn) Oxazepam;
539 [(mm)] (oo) Oxazolam;
540 [(nn)] (pp) Paraldehyde;
541 [(oo)] (qq) Petrichloral;
542 [(pp)] (rr) Phenobarbital;
543 [(qq)] (ss) Pinazepam;
544 [(rr)] (tt) Prazepam;
545 [(ss)] (uu) Quazepam;
546 [(tt)] (vv) Temazepam;
547 [(uu)] (ww) Tetrazepam;
548 [(vv)] (xx) Triazolam;
549 [(ww)] (yy) Zaleplon;
550 [(xx)] (zz) Zolpidem;
551 [(yy)] (aaa) Zopiclone;

552 (3) Any material, compound, mixture, or preparation which contains any
553 quantity of the following substance including its salts, isomers and salts of
554 isomers whenever the existence of such salts, isomers and salts of isomers is
555 possible: fenfluramine;

556 (4) Any material, compound, mixture or preparation containing any
557 quantity of the following substances having a stimulant effect on the central
558 nervous system, including their salts, isomers and salts of isomers:

559 (a) Cathine ((+)-norpseudoephedrine);

- 560 (b) Diethylpropion;
- 561 (c) Fencamfamin;
- 562 (d) Fenproporex;
- 563 (e) Mazindol;
- 564 (f) Mefenorex;
- 565 (g) Modafinil;
- 566 (h) Pemoline, including organometallic complexes and chelates thereof;
- 567 (i) Phentermine;
- 568 (j) Pipradrol;
- 569 (k) Sibutramine;
- 570 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 571 (5) Any material, compound, mixture or preparation containing any
- 572 quantity of the following substance, including its salts:
- 573 (a) butorphanol;
- 574 (b) pentazocine;
- 575 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when
- 576 the substance is the only active medicinal ingredient;
- 577 (7) The department of health and senior services may except by rule any
- 578 compound, mixture, or preparation containing any depressant substance listed in
- 579 subdivision (1) of this subsection from the application of all or any part of sections
- 580 195.010 to 195.320 if the compound, mixture, or preparation contains one or more
- 581 active medicinal ingredients not having a depressant effect on the central nervous
- 582 system, and if the admixtures are included therein in combinations, quantity,
- 583 proportion, or concentration that vitiate the potential for abuse of the substances
- 584 which have a depressant effect on the central nervous system.
- 585 9. The department of health and senior services shall place a substance
- 586 in Schedule V if it finds that:
- 587 (1) The substance has low potential for abuse relative to the controlled
- 588 substances listed in Schedule IV;
- 589 (2) The substance has currently accepted medical use in treatment in the
- 590 United States; and
- 591 (3) The substance has limited physical dependence or psychological
- 592 dependence liability relative to the controlled substances listed in Schedule IV.
- 593 10. The controlled substances listed in this subsection are included in
- 594 Schedule V:
- 595 (1) Any compound, mixture or preparation containing any of the following

596 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in
597 limited quantities as set forth below, which also contains one or more nonnarcotic
598 active medicinal ingredients in sufficient proportion to confer upon the compound,
599 mixture or preparation valuable medicinal qualities other than those possessed
600 by the narcotic drug alone:

601 (a) Not more than two and five-tenths milligrams of diphenoxylate and not
602 less than twenty-five micrograms of atropine sulfate per dosage unit;

603 (b) Not more than one hundred milligrams of opium per one hundred
604 milliliters or per one hundred grams;

605 (c) Not more than five-tenths milligram of difenoxin and not less than
606 twenty-five micrograms of atropine sulfate per dosage unit;

607 (2) Any material, compound, mixture or preparation which contains any
608 quantity of the following substance having a stimulant effect on the central
609 nervous system including its salts, isomers and salts of isomers: pyrovalerone;

610 (3) Any compound, mixture, or preparation containing any detectable
611 quantity of pseudoephedrine or its salts or optical isomers, or salts of optical
612 isomers or any compound, mixture, or preparation containing any detectable
613 quantity of ephedrine or its salts or optical isomers, or salts of optical isomers;

614 (4) Unless specifically exempted or excluded or unless listed in another
615 schedule, any material, compound, mixture, or preparation which contains any
616 quantity of the following substances having a depressant effect on the central
617 nervous system, including its salts: [pregabalin [(S)-3-(aminomethyl)-5-
618 methylhexanoic acid]]

619 (a) **Lacosamide;**

620 (b) **Pregabalin.**

621 11. If any compound, mixture, or preparation as specified in subdivision
622 (3) of subsection 10 of this section is dispensed, sold, or distributed in a pharmacy
623 without a prescription:

624 (1) All packages of any compound, mixture, or preparation containing any
625 detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of
626 optical isomers or ephedrine, its salts or optical isomers, or salts of optical
627 isomers, shall be offered for sale only from behind a pharmacy counter where the
628 public is not permitted, and only by a registered pharmacist or registered
629 pharmacy technician; and

630 (2) Any person purchasing, receiving or otherwise acquiring any
631 compound, mixture, or preparation containing any detectable quantity of

632 pseudoephedrine, its salts or optical isomers, or salts of optical isomers or
633 ephedrine, its salts or optical isomers, or salts of optical isomers shall be at least
634 eighteen years of age; and

635 (3) The pharmacist, intern pharmacist, or registered pharmacy technician
636 shall require any person, prior to their purchasing, receiving or otherwise
637 acquiring such compound, mixture, or preparation to furnish suitable photo
638 identification that is issued by a state or the federal government or a document
639 that, with respect to identification, is considered acceptable and showing the date
640 of birth of the person;

641 (4) The seller shall deliver the product directly into the custody of the
642 purchaser.

643 12. Pharmacists, intern pharmacists, and registered pharmacy technicians
644 shall implement and maintain an electronic log of each transaction. Such log
645 shall include the following information:

646 (1) The name, address, and signature of the purchaser;

647 (2) The amount of the compound, mixture, or preparation purchased;

648 (3) The date and time of each purchase; and

649 (4) The name or initials of the pharmacist, intern pharmacist, or
650 registered pharmacy technician who dispensed the compound, mixture, or
651 preparation to the purchaser.

652 13. Each pharmacy shall submit information regarding sales of any
653 compound, mixture, or preparation as specified in subdivision (3) of subsection 10
654 of this section in accordance with transmission methods and frequency
655 established by the department by regulation;

656 14. No person shall dispense, sell, purchase, receive, or otherwise acquire
657 quantities greater than those specified in this chapter.

658 15. All persons who dispense or offer for sale pseudoephedrine and
659 ephedrine products in a pharmacy shall ensure that all such products are located
660 only behind a pharmacy counter where the public is not permitted.

661 16. Any person who knowingly or recklessly violates the provisions of
662 subsections 11 to 15 of this section is guilty of a class A misdemeanor.

663 17. The scheduling of substances specified in subdivision (3) of subsection
664 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply
665 to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel
666 capsule form or to any compound, mixture, or preparation specified in subdivision
667 (3) of subsection 10 of this section which must be dispensed, sold, or distributed

668 in a pharmacy pursuant to a prescription.

669 18. The manufacturer of a drug product or another interested party may
670 apply with the department of health and senior services for an exemption from
671 this section. The department of health and senior services may grant an
672 exemption by rule from this section if the department finds the drug product is
673 not used in the illegal manufacture of methamphetamine or other controlled or
674 dangerous substances. The department of health and senior services shall rely
675 on reports from law enforcement and law enforcement evidentiary laboratories in
676 determining if the proposed product can be used to manufacture illicit controlled
677 substances.

678 19. The department of health and senior services shall revise and
679 republish the schedules annually.

680 20. The department of health and senior services shall promulgate rules
681 under chapter 536, RSMo, regarding the security and storage of Schedule V
682 controlled substances, as described in subdivision (3) of subsection 10 of this
683 section, for distributors as registered by the department of health and senior
684 services.

685 21. Logs of transactions required to be kept and maintained by this
686 section and section 195.417 shall create a rebuttable presumption that the person
687 whose name appears in the logs is the person whose transactions are recorded in
688 the logs.

✓

Copy